Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021
Previous Archive
31 March 2020 | Story Leonie Bolleurs | Photo Supplied
UFS Covid-19 vaccine research team
Prof Robert Bragg and members of the Veterinary Biotechnology research group believe that finding a vaccine for COVID-19 will not be a ‘quick fix’. From the left are: Prof Bragg, Samantha McCarlie, Liese Kilian, and Dr Charlotte Boucher-van Jaarsveld. The photo was taken during the World Veterinary Poultry Association congress in Thailand in 2019.

On 31 March 2020, there were 804 061 coronavirus cases and 39 064 deaths globally due to the outbreak. According to media reports, there is still no licensed vaccine for COVID-2019 – the cause of our current global health emergency.  

Prof Robert Bragg, researcher at the University of the Free State (UFS), says this is without a doubt the most pressing research need in the world today. 

The Veterinary Biotechnology research group in the Department of Microbial, Biochemical, and Food Biotechnology at the UFS recently submitted an article for publication on the design of a possible COVID-19 vaccine, based on work they have done on infectious bronchitis virus (also a coronavirus). The article, authored by the group of which Prof Bragg is a member, is titled: A sub-unit vaccine produced in 'Yarrowia lipolytica' against COVID-19: Lessons learnt from infectious bronchitis virus. 

The research group, consisting of researchers and postgraduate students, is mostly looking at strategies for improved disease control, mainly in avian species, through vaccine development, treatment, and biosecurity.

Prof Bragg says their main aim with this study was to get the research out there so that the bigger pharmaceutical companies could take up the design of a possible COVID-19 vaccine and assist with the development of a vaccine. 

He says the research group’s role in this lengthy process would be to express the protein, which could be used in the development of a possible vaccine. “Thereafter, it will have to be taken up by a vaccine manufacturer to get the vaccine made and to the market.”

Developing a vaccine
Liese Kilian, a member of the research group, finished writing up her MSc thesis in Microbiology in the UFS Department of Microbial, Biochemical, and Food Biotechnology in December 2019 – the same time that COVID-19 originated in China. She has been working on the development of an edible sub-unit vaccine against the infectious bronchitis virus (IBV), which is a widespread avian coronavirus. This virus is specific to poultry and is different from COVID-19. 

Kilian’s project was conducted under the supervision of Prof Bragg and Dr Charlotte Boucher-van Jaarsveld. Dr Boucher-van Jaarsveld is a research fellow in the university’s Department of Microbial, Biochemical and Food Biotechnology.

Kilian, with the assistance of Samantha Mc Carlie, currently a master’s student in the research group, substituted the genetic code of the IBV with the genetic code of the COVID-19 virus, which were already published at that stage. Thus, a gene for the development of a possible sub-unit vaccine against the S1 spike protein of COVID-19 was developed for expression in the same yeast strain used to express the spike protein of IBV. A sub-unit vaccine can be described as part of a pathogen, triggering an immune response against the pathogen from which it is derived.

After Killian successfully developed the gene for this study, she expressed the S1 spike protein of the IBV in a yeast-based expression system developed by the research group. Dr Boucher-van Jaarsveld says this simply means that the yeast takes up the foreign genetic material (viral gene) into its own genetic make-up and makes more of this protein as if it is part of the yeast’s normal material. 

“The images of COVID-19 are being shown constantly in the media and the ‘spikes’ can be seen on all of these images. These spikes are very typical for all coronaviruses and there is some level of similarity between the structure of these spikes in many of the coronaviruses,” Prof Bragg adds.

According to the World Health Organisation, the spike protein is a promising candidate for a sub-unit vaccine due to its immunogenicity and safety, as well as manufacturing and stability considerations during large-scale development.

Prof Bragg says there are many different expression systems that are widely used. Producing the sub-unit vaccine in a yeast species is beneficial for the work they are doing. A yeast expression system is favourable as large-scale production, is less expensive compared to mammalian cell lines, and can be applied as an edible vaccine.

“The technology to grow massive volumes of yeast are also very well established. This, after all, is how beer is made!” Prof Bragg says. Dr Boucher-van Jaarsveld adds: “The expression of an antigen is not necessarily just geared towards vaccines but can also be used in the development of diagnostic tests to screen populations for infections.”

Working with other researchers
“Now that the situation is all but out of control, we maybe need to investigate the possibilities of working with other key researchers at the UFS as well as other universities in South Africa to develop the vaccine or diagnostic reagents locally. Discussions on this aspect are already underway.”

Several other universities in South Africa are also working to find a cure for the virus. Government availed funding for more research on the matter. According to Higher Education, Science and Technology Minister, Blade Nzimande, the University of Cape Town, the Council for Scientific and Industrial Research, as well as the Vaccines Institute of Southern Africa are working on the development of a vaccine.

Prof Bragg expressed the hope of obtaining funding for this work. “Because without funding, we will not be able to do anything with this data,” he says. They are currently investigating different funding options. 

“The sooner we start on the development of a vaccine, the sooner there will be one, but it will not be a ‘quick fix’. It must be stressed that, even if vaccine development is fast-tracked through the regulatory bodies, it will take many months (if not years) to move from the laboratory to the first human experimentation. It will take even longer before any human vaccine can be rolled out,” says Prof Bragg.



News Archive

Esteemed Tutu family honorary guests at first intercontinental symposium
2013-10-08

 

08 October 2013
Photo: Karina Turok

The University of the Free State (UFS) will be hosting a visit by Archbishop Desmond Tutu and Mrs Leah Tutu. The occasion is to launch the Annual Intercontinental Leah Tutu Symposium on rape and violence against women in honour of Mrs Tutu, who has been an outspoken advocate of women’s rights and the sanctity of family life.

The Inaugural Intercontinental Leah Tutu Symposium will take place on:

Thursday 17 October 2013
12:00-14:00
Scaena Theatre


The launch of the Annual Intercontinental Leah Tutu Symposium is organised by Profs Pumla Gobodo-Madikizela (who hosts the Dialogue between Science and Society lecture series) and Heidi Hudson (Director of the Centre for Africa Studies). The Inaugural Intercontinental Leah Tutu Symposium will feature gender and policy analyst Nomboniso Gasa as keynote speaker and Sheila Meintjes, Wits University professor with expertise in gender politics, violence and conflict transformation. The event will also feature voices of survivors of rape and sexual violence, including Johannesburg businesswoman and social entrepreneur, Andy Kawa, who is a survivor of rape and started the organisation Enuf is Enuf to campaign for an end to rape and sexual violence.

On Mrs Tutu’s 80th birthday, during the family’s visit to the UFS, Archbishop Desmond Tutu will also be in conversation with the Vice-Chancellor and Rector, Prof Jonathan Jansen, at a public event: Celebration of a partnership: Archbishop Tutu pays tribute to his wife, on the topic: Man to Man: The Meaning of Leah in My Life.

Thursday 17 October 2013
16:30-18:00
Centenary Complex


The public event is part of the Dialogue between Science and Society lecture series, in collaboration with Mrs Grace Jansen and the Tutu Legacy Foundation.

Please RSVP to Anja Pienaar at pienaaran@ufs.ac.za or +27(0)51 401 7330 or Jo-Anne Naidoo at naidooja@ufs.ac.za or +27(0)51 401 7160.

Two of their daughters, Rev Mpho Tutu and Dr Thandeka Tutu-Gxashe, will accompany Archbishop Desmond and Mrs Leah Tutu.

Short Bio of Mrs Leah Tutu

Nomalizo Leah Tutu is an outspoken advocate for the rights of women and the sanctity of family life. She was awarded an Honorary Doctorate in 2000 by the National Louis University in Atlanta for her commitment to human rights and support of her husband’s work. She is patron of the Phelophepa Train, a health project that brings medical care to people living in remote areas of South Africa. She is also a patron of the Tshwaranang Centre that provides legal advocacy to end violence against women. With Archbishop Tutu, Mrs Tutu is a patron of the Tygerberg Children’s Hospital in Cape Town. She, Archbishop Tutu, and family established the Desmond and Leah Tutu Legacy Foundation in 2012.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept